Taiwan
· Delayed Price · Currency is TWD Lumosa Therapeutics Statistics
Total Valuation
Lumosa Therapeutics has a market cap or net worth of TWD 50.30 billion. The enterprise value is 49.73 billion.
| Market Cap | 50.30B |
| Enterprise Value | 49.73B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Lumosa Therapeutics has 164.93 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Shares Outstanding | 164.93M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.49% |
| Owned by Institutions (%) | 4.44% |
| Float | 89.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 36.76 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -177.15 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -167.52 |
Financial Position
The company has a current ratio of 4.09, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.09 |
| Quick Ratio | 3.22 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.04 |
| Interest Coverage | -3,275.48 |
Financial Efficiency
Return on equity (ROE) is -19.22% and return on invested capital (ROIC) is -14.14%.
| Return on Equity (ROE) | -19.22% |
| Return on Assets (ROA) | -12.57% |
| Return on Capital (ROIC) | -14.14% |
| Revenue Per Employee | 1.02M |
| Profits Per Employee | -5.97M |
| Employee Count | 47 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0.12 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +421.27% in the last 52 weeks. The beta is 0.37, so Lumosa Therapeutics's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +421.27% |
| 50-Day Moving Average | 256.01 |
| 200-Day Moving Average | 186.38 |
| Relative Strength Index (RSI) | 63.53 |
| Average Volume (20 Days) | 953,583 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Lumosa Therapeutics had revenue of TWD 47.71 million and -280.72 million in losses. Loss per share was -1.74.
| Revenue | 47.71M |
| Gross Profit | 35.12M |
| Operating Income | -347.20M |
| Pretax Income | -293.50M |
| Net Income | -280.72M |
| EBITDA | -335.08M |
| EBIT | -347.20M |
| Loss Per Share | -1.74 |
Balance Sheet
The company has 609.05 million in cash and 10.54 million in debt, giving a net cash position of 598.50 million or 3.63 per share.
| Cash & Cash Equivalents | 609.05M |
| Total Debt | 10.54M |
| Net Cash | 598.50M |
| Net Cash Per Share | 3.63 |
| Equity (Book Value) | 1.39B |
| Book Value Per Share | 8.30 |
| Working Capital | 610.46M |
Cash Flow
In the last 12 months, operating cash flow was -283.51 million and capital expenditures -13.34 million, giving a free cash flow of -296.85 million.
| Operating Cash Flow | -283.51M |
| Capital Expenditures | -13.34M |
| Free Cash Flow | -296.85M |
| FCF Per Share | -1.80 |
Margins
| Gross Margin | 73.61% |
| Operating Margin | -727.69% |
| Pretax Margin | -615.13% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -622.16% |
Dividends & Yields
Lumosa Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.02% |
| Shareholder Yield | -0.02% |
| Earnings Yield | -0.57% |
| FCF Yield | -0.59% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Lumosa Therapeutics has an Altman Z-Score of 52.78.
| Altman Z-Score | 52.78 |
| Piotroski F-Score | n/a |